An oral presentation will highlight results from the Phase 2 ASTX030-01 trial, a multicenter, randomized, open-label, crossover trial comparing the all-oral combination of azacitidine and cedazuridine ...
Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia. Oral hypomethylating agents (HMAs ...
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome Patients were randomly assigned to ...
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Twenty-three patients received ivosidenib ...
Older adults with acute myeloid leukemia (AML) saw increased overall and relapse-free survival, as well as preserved quality of life, following oral administration of 300-mg azacitidine. The ...
In the past, myelodysplastic syndromes were managed primarily by supportive care measures, which had limited effects on symptomatic cytopenias or on the rate of leukemic transformation of these ...
The MarketWatch News Department was not involved in the creation of this content. -- Two oral presentations will highlight Phase 2 results from the ASTX030-01 trial of oral azacitidine and ...
PRINCETON, N.J., Dec. 8, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data ...
Two oral presentations will highlight Phase 2 results from the ASTX030-01 trial of oral azacitidine and cedazuridine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback